Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement.

Joshua Cohen is a Boston-based writer who covers health policy. Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic disorders and cancers.

(Reuters) - Carlyle Group and SK Capital Partners increased their upfront offer to take over gene therapy maker bluebird bio, the companies said on Wednesday. Shares of bluebird bio jumped over 50 ...

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers Carlyle and SK Capital to extend their offer deadline once again.

Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) of $6.84 per ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. In a revised merger agreement, Carlyle and SK Capital Partners are now ...

The Jacksonville Aviation Authority will vote on nearly $35 million in airport improvements and incentives to attract a passenger jet manufacturer codenamed Project Bluebird to Cecil Airport.

Under the terms of the amended agreement, Bluebird stockholders can elect to receive either the original offer of $3.00 per share in cash plus a contingent value right (CVR) of $6.84 per share in ...

Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share with no CVR SOMERVILLE, Mass.

May 14 (Reuters) - Carlyle Group (CG.O), opens new tab and SK Capital Partners increased their upfront offer to take over gene therapy maker bluebird bio (BLUE.O), opens new tab, the companies ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK ...

They began with 2027 defensive end Javion Herrington, a two-sport athlete from Somerset Academy Canyons High School. He announced the offer on social media last week. Herrington had a strong ...